EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(−) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(+) pts could be considered.

中文翻译：

---

评估接受顺铂，5-氟尿嘧啶联合或不联合多西紫杉醇治疗的局部晚期不可切除的头颈部鳞状细胞癌（HNSCC）患者的肿瘤HPV状况对预后的影响：EORTC 24971研究的子集分析

EORTC 24971是一项III期试验，在局部进展的无进展（PFS）和总体生存率（OS）方面，TPF（多西他赛，顺铂，5-氟尿嘧啶）诱导方案优于PF（顺铂/ 5-氟尿嘧啶）不可切除的头颈部鳞状细胞癌。我们对前瞻性收集的数据进行了回顾性分析，旨在评估是否只有HPV（-）患者（pts）从多西紫杉醇中加入PF才能受益，在这种情况下，可以考虑加强HPV（+）pts的诱导治疗。